The Role of Defensins in the Pathogenesis of Inflammatory Bowel Disease;Die Rolle der Defensine in der Pathogenese Chronisch-entzündlicher Darmerkrankungen

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 4, 2004, Pages 333-338

  Schmid, M ^a   Fellermann, K ^a   Wehkamp, J ^a   Herrlinger, K ^a   Stange, Eduard F ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Crohn's disease; Defensins; Innate immunity; Pathogenesis

Indexed keywords

ALPHA DEFENSIN; BETA DEFENSIN; BETA DEFENSIN 2; BETA DEFENSIN 3; DEFENSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTIBACTERIAL ACTIVITY; AUTOIMMUNITY; CROHN DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOREGULATION; INTESTINE MUCOSA; PROTEIN EXPRESSION; REVIEW; ULCERATIVE COLITIS;

ANIMALS; BACTERIAL INFECTIONS; DEFENSINS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES; INTESTINES;

EID: 2542548256     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813072     Document Type: Review

References (67)

1. Moss MT, Sanderson JD, Tizard ML et al. Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues. Gut 1992; 33: 1209-1213
2. McFadden JJ, Butcher PD, Chiodini R et al. Crohn's disease-isolated mycobacteria are identical to Mycobacterium paratuberculosis, as determined by DNA probes that distinguish between mycobacterial species. J Clin Microbiol 1987; 25: 796-801
3. Ryan P, Bennett MW, Aarons S et al. PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut 2002; 51: 665-670
4. Liu Y, van Kruiningen HJ, West AB et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108: 1396-1404
5. Darfeuille-Michaud A, Neut C, Barnich N et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115: 1405-1413
6. Wakefield AJ, Ekbom A, Dhillon AP et al. Crohn's disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995; 108: 911-916
7. Neut C, Bulois P, Desreumaux P et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002; 97: 939-946
8. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm Bowel Dis 1998; 4: 29-39
9. D'Haens GR, Geboes K, Peeters M et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267
10. Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66: 5224-5231
11. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54
12. Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-455
13. Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242
14. Boman HG. Gene-encoded peptide antibiotics and the concept of innate immunity: an update review. Scand J Immunol 1998; 48: 15-25
15. Fellermann K, Stange EF. Defensins innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001; 13: 771-776
16. Cunliffe RN, Mahida YR. Antimicrobial peptides in innate intestinal host defence. Gut 2000; 47: 16-17
17. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14: 96-102
18. Harder J, Siebert R, Zhang Y et al. Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics 1997: 46: 472-475
19. Liu L, Zhao C, Heng HH et al. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997; 43: 316-320
20. Liu L, Wang L, Jia HP et al. Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene 1998; 222: 237-244
21. Wilson CL, Ouellette AJ, Satchell DP et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286: 113-117
22. Becker MN, Diamond G, Verghese MW et al. CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000; 275: 29 731-29 736
23. Diamond G, Kaiser V, Rhodes J et al. Transcriptional regulation of beta-defensin gene expression in tracheal epithelial cells. Infect Immun 2000; 68: 113-119
24. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606
25. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603
26. Ogura Y, Inohara N, Benito et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276: 4812-4818
27. Hisamatsu T, Suzuki M, Reinecker HC et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124: 993-1000
28. Porter EM, van Dam E, Valore EV et al. Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997; 65: 2396-2401
29. Harder J, Bartels J, Christophers E et al. A peptide antibiotic from human skin. Nature 1997; 387: 861
30. Harder J, Bartels J, Christophers E et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713
31. Garcia JR, Jaumann F, Schulz S et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-264
32. Fujii G, Selsted ME, Eisenberg D. Defensins promote fusion and lysis of negatively charged membranes. Protein Sci 1993; 2: 1301-1312
33. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 1994; 3: 1362-1373
34. Salzman NH, Ghosh D, Huttner KM et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003; 422: 522-526
35. Salzman NH, Chou MM, de Jong H et al. Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect Immun 2003; 71: 1109-1115
36. Smith JJ, Travis SM, Greenberg EP et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-236
37. Goldman MJ, Anderson GM, Stolzenberg ED et al. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-560
38. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160
39. Cunliffe RN, Kamal M, Rose FR et al. Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol 2002; 55: 298-304
40. Wehkamp J, Schwind B, Herrlinger KR et al. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002; 47: 1349-1355
41. Cunliffe RN, Rose FR, Keyte J et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001; 48: 176-185
42. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10: 445-456
43. Wehkamp J, Harder J, Weichenthal M et al. Pathomechanism of Crohn's disease NOD2 (CARD 15) mutation: Deficient mucosal antimicrobial peptide (defensin) expression. Gut 2003; 52 (Suppl VI) A1 (OP-G-2, abstract)
44. Ogura Y, Lala S, Xin W et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003; 52: 1591-1597
45. O'Neil DA, Porter EM, Elewaut D et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999; 163: 6718-6724
46. Wehkamp J, Fellermann K, Herrlinger KR et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 745-752
47. Wehkamp J, Harder J, Weichenthal M et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2003; 9: 215-223
48. Fahlgren A, Hammarstrom S, Danielsson A et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol 2003; 131: 90-101
49. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550-562
50. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075
51. Colombel JF, Lemann M, Cassagnou M et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J 1999; 94: 674-678
52. Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332
53. Arnold GL, Beaves MR, Pryjdun VO et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15
54. Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621
55. Prantera C, Scribano ML, Falasco G et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409
56. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79: 533-540
57. Brandt LJ, Bernstein LH, Boley SJ et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-387
58. Mantzaris GJ, Archavlis E, Christoforidis P et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92: 454-456
59. Mantzaris GJ, Petraki K, Archavlis E et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974
60. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-1212
61. Mantzaris GJ, Hatzis A, Kontogiannis P et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46
62. Turunen UM, Farkkila MA, Hakala K et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-1078
63. Kruis W, Schutz E, Fric P et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858
64. Rembacken BJ, Snelling AM, Hawkey PM et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-639
65. Schlee M, Wehkamp J, Harder J et al. Das Probiotikum E. coli Nissle 1917 induziert humanes beta Defensin-2 in Abhängigkeit von NFkB in intestinalen Epithelzellen. Z Gastroenterol 2003; 41: 734 (abstract)
66. Sartor RB. Innate immunity in the pathogenesis and therapy of IBD. J Gastroenterol 2003; 38: 43-47
67. Fellermann K, Wehkamp J, Herrlinger KR et al. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003; 15: 627-634